Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc. provides laboratory services spanning diagnostics and drug development laboratory capabilities for doctors, hospitals, pharmaceutical companies, researchers and patients. News about LH commonly covers earnings releases and guidance, dividend declarations, specialty and companion diagnostics, oncology testing, drug-screening products, and collaborations that expand access to advanced laboratory services.
Company updates also address Labcorp's Diagnostics Laboratories and Biopharma Laboratory Services activities, including FDA-cleared or FDA-approved tests, pediatric diagnostics development, real-world data platforms, digital pathology and AI-enabled laboratory operations. Recurring announcements connect Labcorp's national diagnostic infrastructure with health systems, biopharmaceutical customers and technology partners.
Labcorp (NYSE: LH) announced that the U.S. Food and Drug Administration has approved its PGDx elio® tissue complete CDx as a companion diagnostic for patients with advanced melanoma.
The test helps identify patients whose tumors harbor specific BRAF V600E/K variants, indicating they may benefit from FDA‑approved BRAF inhibitor and BRAF/MEK inhibitor combination therapies. According to Labcorp, melanoma is the deadliest form of skin cancer, and targeted therapies are an important option for stage IV patients with BRAF alterations. The kit‑based CDx can be used by qualified healthcare professionals across hospitals and clinical laboratories, enabling institutions to implement testing on‑site, retain samples and data, and potentially support future clinical research. This approval also expands Labcorp’s precision medicine portfolio of tissue‑ and liquid‑based oncology diagnostics designed to support personalized care.
Labcorp (NYSE: LH) announced nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic to determine PTEN protein loss in tumors from patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for combination treatment with AstraZeneca's TRUQAP (capivasertib), abiraterone acetate and prednisone.
According to Labcorp, the test is now offered through its national laboratory network, expanding access to FDA-approved companion diagnostics and supporting precision oncology by providing PTEN biomarker information to guide personalized prostate cancer treatment decisions.
Labcorp (NYSE: LH) reported 2026 Q2 revenue of $3.73 billion, up 5.8% year over year, with operating margin rising to 12.1% and adjusted operating margin to 15.8%. Diluted EPS was $3.64 vs. $2.84, and adjusted EPS was $4.99 vs. $4.35.
Diagnostics revenue grew 5.5% with 18.0% adjusted operating margin, while Biopharma Laboratory Services revenue rose 6.5% and margin reached 17.0%. Labcorp raised 2026 enterprise revenue growth guidance to 5.4%–6.3% and adjusted EPS to $18.10–$18.55. The company added $1.0 billion to its share repurchase authorization (total remaining $1.4 billion), maintained a quarterly dividend of $0.72 per share, and highlighted oncology test launches, consumer health offerings, expanded Epic integration, and a Biopharma backlog of $8.73 billion.
Labcorp (NYSE: LH) announced the launch of the Marker by Labcorp™ Genetic Health Panel, a consumer-focused test analyzing 163 genes associated with hereditary cancer, cardiovascular and metabolic conditions linked to more than 100 medically actionable health conditions. The panel is offered through Labcorp OnDemand and includes access to licensed genetic counselors for result interpretation and next-step guidance.
According to Labcorp, consumers purchase the test online, complete a blood draw at one of over 2,200 patient service centers, and receive results via Labcorp’s secure portal and MyLabcorp AI-powered mobile platform. The service integrates clinical genetic testing, specimen collection and counseling into a single experience and will be available starting August 3, 2026.
Labcorp (NYSE: LH) announced that its board declared a quarterly cash dividend of $0.72 per share on common stock. The dividend is payable on September 11, 2026 to shareholders of record at the close of business on August 28, 2026.
Labcorp (NYSE: LH) plans to release its second quarter 2026 financial results before the market opens on Thursday, July 30, 2026. The company will host a webcast at 9:00 a.m. ET to discuss the results, with materials and replay available on its investor relations website.
Labcorp (NYSE: LH) announced nationwide availability of ColoSense, the first and only FDA-approved RNA-based at-home colorectal cancer screening test. Developed by Geneoscopy and offered via Labcorp, it detects biomarkers for colorectal cancer and advanced adenomas with 93% sensitivity and 100% sensitivity for stage I disease.
The test has national Medicare and Medicare Advantage coverage for eligible beneficiaries after a June CMS NCD update, with additional commercial coverage. ColoSense is indicated for adults 45–85 at average risk, aligns with ACS and NCCN guidelines, and features a simplified, cleaner collection kit mailed directly to patients.
Labcorp (NYSE: LH) is collaborating with the Alliance for Clinical Trials in Oncology on a national, multicenter trial for newly diagnosed colorectal cancer patients. The NCI-sponsored study will test proactive outreach to increase cascade germline genetic testing in at-risk relatives and evaluate multigene panel testing’s impact on care, with Labcorp as exclusive genetic testing provider using its Invitae platform.
Labcorp (NYSE: LH) launched an expanded DPYD Genotyping test to identify cancer patients at increased risk for severe or life-threatening side effects from fluoropyrimidine chemotherapy.
The test now covers all AMP-recommended Tier 1 and Tier 2 DPYD variants, aligning with FDA, NCCN and CPIC guidance and is available to clinicians through Labcorp.
Labcorp (NYSE: LH) announced it will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
Investors can access a live webcast and a recorded archive for 90 days on Labcorp's investor relations website.